AKZO NOBEL'S ORGANON ENTERS LICENCE AGREEMENT WITH GENAISSANCE

Organon, a division of Akzo Nobel NV, announced that it has entered a licence agreement with US-based company Genaissance Pharmaceuticals on pharmacogenetic research. The financial details were not disclosed. Organon and Genaissance will cooperate in developing Genaissance's HAP Technology, which is used to develop genetic markers to determine the effectiveness of medication on individuals, and develop diagnostic products based on those markers.

Forbes (http://www.forbes.com/home/feeds/afx/2005/07/18/afx2142790.html)